Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
Novartis
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, developing innovative medicines in therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology.
Company Info
Sector:Diversified Biopharmaceuticals
Headquarters:Basel, Switzerland
Founded:1996
Website:www.novartis.com/
Recent News
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
Novartis has exclusively licensed a preclinical radioligand therapy from Suzhou-based BoomRay Pharmaceuticals in a deal that could reach up to $900 million.
Novartis pays Sironax $125M to acquire brain delivery platform
News from Fierce Biotech: Novartis pays Sironax $125M to acquire brain delivery platform
Novartis' TREM2 drug fails Phase 2 ALS trial
The Swiss pharma giant is ending work on VHB937/lifonebart in ALS, according to a letter from the company's clinical development team.
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops — latest biotech and pharma news.
Novartis drags peers down with triple asset stumble
Novartis drags peers down with triple asset stumble — latest biotech and pharma news.
Novartis investor calls for board overhaul after costly setbacks
Novartis investor calls for board overhaul after costly setbacks — latest pharmaceutical industry news.
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly
Novartis' Phase 3 pelacarsen study miss in cardiovascular disease raises competitive stakes for Amgen and Eli Lilly in the space.
Novartis halts CAR-T trials after patient deaths
Article from Pharmaphorum about Novartis halts CAR-T trials after patient deaths.
Novartis Lp(a) drug fails closely watched ph. 3 trial
Novartis Lp(a) drug fails closely watched ph. 3 trial
Roche, GSK, Novartis, MFN, Akeso and more—Fierce Pharma Asia
Article from Fierce Pharma about Roche, GSK, Novartis, MFN, Akeso and more—Fierce Pharma Asia.
Novartis teams with Olympian Laviai Nielsen on MS campaign
Article from Fierce Pharma about Novartis teams with Olympian Laviai Nielsen on MS campaign.
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Novartis telegraphs 130 job cuts in Switzerland
Novartis telegraphs 130 job cuts in Switzerland
Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M
Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M
Novartis' Pluvicto unlocks substantial new patient pool
Novartis' radioligand therapy Pluvicto leaps ahead into earlier manifestations of prostate cancer, unlocking a substantially larger patient pool.
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
Novartis has discontinued a mid-stage radioligand therapy program as Pluvicto continues to exceed sales expectations.
For Novartis' CEO, China deals aren't a strategy shift — just where the science is
Novartis' CEO says its latest China deals are not a strategy shift — just following where the science is.
Novartis climbs on upbeat drug sales as key readouts loom
Novartis stock climbed on upbeat Q2 drug sales as key readouts loom.
Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal
Novartis CEO explained why he ended his ADC holdout for the $1.5B Myricx deal.
Novartis slashes New Jersey workforce again, cutting 322 employees
Novartis slashes New Jersey workforce again, cutting 322 employees (reported by BioSpace)
Novartis dismisses 322 more staffers based out of US headquarters
Novartis dismisses 322 more staffers based out of US headquarters (reported by Fierce Pharma)
Fosun pays $32M to join Lilly and Novartis in psoriasis market
Fosun pays $32M to join Lilly and Novartis in psoriasis market — Fierce Biotech coverage of biopharma industry developments.
Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product
Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product
Novartis, Antares stars align in cancer deal that could top $1.9B
Novartis and Antares Therapeutics are shooting for the stars, launching a joint mission to develop small molecule oncology therapies.
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
Leadership Team
Vasant Narasimhan
Chief Executive Officer
Careers & Job Openings
No active job listings. Check back later.